195 related articles for article (PubMed ID: 10607427)
21. Stereoselective interactions of the enantiomers of chromanol 293B with human voltage-gated potassium channels.
Yang IC; Scherz MW; Bahinski A; Bennett PB; Murray KT
J Pharmacol Exp Ther; 2000 Sep; 294(3):955-62. PubMed ID: 10945846
[TBL] [Abstract][Full Text] [Related]
22. Kv1.2-containing K+ channels regulate subthreshold excitability of striatal medium spiny neurons.
Shen W; Hernandez-Lopez S; Tkatch T; Held JE; Surmeier DJ
J Neurophysiol; 2004 Mar; 91(3):1337-49. PubMed ID: 13679409
[TBL] [Abstract][Full Text] [Related]
23. K+ channels and T-cell synapses: the molecular background for efficient immunomodulation is shaping up.
Matkó J
Trends Pharmacol Sci; 2003 Aug; 24(8):385-9. PubMed ID: 12915045
[TBL] [Abstract][Full Text] [Related]
24. NH2-terminal inactivation peptide binding to C-type-inactivated Kv channels.
Kurata HT; Wang Z; Fedida D
J Gen Physiol; 2004 May; 123(5):505-20. PubMed ID: 15078918
[TBL] [Abstract][Full Text] [Related]
25. Cholesterol modifies the gating of Kv1.3 in human T lymphocytes.
Hajdú P; Varga Z; Pieri C; Panyi G; Gáspár R
Pflugers Arch; 2003 Mar; 445(6):674-82. PubMed ID: 12632187
[TBL] [Abstract][Full Text] [Related]
26. UK-78,282, a novel piperidine compound that potently blocks the Kv1.3 voltage-gated potassium channel and inhibits human T cell activation.
Hanson DC; Nguyen A; Mather RJ; Rauer H; Koch K; Burgess LE; Rizzi JP; Donovan CB; Bruns MJ; Canniff PC; Cunningham AC; Verdries KA; Mena E; Kath JC; Gutman GA; Cahalan MD; Grissmer S; Chandy KG
Br J Pharmacol; 1999 Apr; 126(8):1707-16. PubMed ID: 10372812
[TBL] [Abstract][Full Text] [Related]
27. Identification of a new class of inhibitors of the voltage-gated potassium channel, Kv1.3, with immunosuppressant properties.
Schmalhofer WA; Bao J; McManus OB; Green B; Matyskiela M; Wunderler D; Bugianesi RM; Felix JP; Hanner M; Linde-Arias AR; Ponte CG; Velasco L; Koo G; Staruch MJ; Miao S; Parsons WH; Rupprecht K; Slaughter RS; Kaczorowski GJ; Garcia ML
Biochemistry; 2002 Jun; 41(24):7781-94. PubMed ID: 12056910
[TBL] [Abstract][Full Text] [Related]
28. The inhibitory effect of copper ions on lymphocyte Kv1.3 potassium channels.
Teisseyre A; Mozrzymas JW
J Physiol Pharmacol; 2006 Jun; 57(2):301-14. PubMed ID: 16845233
[TBL] [Abstract][Full Text] [Related]
29. Inhibitors of potassium channels KV1.3 and IK-1 as immunosuppressants.
Pegoraro S; Lang M; Dreker T; Kraus J; Hamm S; Meere C; Feurle J; Tasler S; Prütting S; Kuras Z; Visan V; Grissmer S
Bioorg Med Chem Lett; 2009 Apr; 19(8):2299-304. PubMed ID: 19282171
[TBL] [Abstract][Full Text] [Related]
30. Kv1.3 potassium channels as a therapeutic target in multiple sclerosis.
Rangaraju S; Chi V; Pennington MW; Chandy KG
Expert Opin Ther Targets; 2009 Aug; 13(8):909-24. PubMed ID: 19538097
[TBL] [Abstract][Full Text] [Related]
31. Effects of various K+ channel blockers on spontaneous glycine release at rat spinal neurons.
Shoudai K; Nonaka K; Maeda M; Wang ZM; Jeong HJ; Higashi H; Murayama N; Akaike N
Brain Res; 2007 Jul; 1157():11-22. PubMed ID: 17555723
[TBL] [Abstract][Full Text] [Related]
32. The 'functional' dyad of scorpion toxin Pi1 is not itself a prerequisite for toxin binding to the voltage-gated Kv1.2 potassium channels.
Mouhat S; Mosbah A; Visan V; Wulff H; Delepierre M; Darbon H; Grissmer S; De Waard M; Sabatier JM
Biochem J; 2004 Jan; 377(Pt 1):25-36. PubMed ID: 12962541
[TBL] [Abstract][Full Text] [Related]
33. Immunosuppressive effects of a Kv1.3 inhibitor.
Shah K; Tom Blake J; Huang C; Fischer P; Koo GC
Cell Immunol; 2003 Feb; 221(2):100-6. PubMed ID: 12747950
[TBL] [Abstract][Full Text] [Related]
34. Biophysical and pharmacological aspects of K+ channels in T lymphocytes.
Panyi G
Eur Biophys J; 2005 Aug; 34(6):515-29. PubMed ID: 16184309
[TBL] [Abstract][Full Text] [Related]
35. Immunosuppressive evidence of Tityus serrulatus toxins Ts6 and Ts15: insights of a novel K(+) channel pattern in T cells.
Pucca MB; Bertolini TB; Cerni FA; Bordon KC; Peigneur S; Tytgat J; Bonato VL; Arantes EC
Immunology; 2016 Feb; 147(2):240-50. PubMed ID: 26595158
[TBL] [Abstract][Full Text] [Related]
36. Effects of anorexinogen agents on cloned voltage-gated K(+) channel hKv1.5.
Perchenet L; Hilfiger L; Mizrahi J; Clément-Chomienne O
J Pharmacol Exp Ther; 2001 Sep; 298(3):1108-19. PubMed ID: 11504808
[TBL] [Abstract][Full Text] [Related]
37. Novel alpha-KTx sites in the BK channel and comparative sequence analysis reveal distinguishing features of the BK and KV channel outer pore.
Giangiacomo KM; Becker J; Garsky C; Schmalhofer W; Garcia ML; Mullmann TJ
Cell Biochem Biophys; 2008; 52(1):47-58. PubMed ID: 18815746
[TBL] [Abstract][Full Text] [Related]
38. K+ channel blockers: novel tools to inhibit T cell activation leading to specific immunosuppression.
Panyi G; Possani LD; Rodríguez de la Vega RC; Gáspár R; Varga Z
Curr Pharm Des; 2006; 12(18):2199-220. PubMed ID: 16787250
[TBL] [Abstract][Full Text] [Related]
39. Benzamide derivatives as blockers of Kv1.3 ion channel.
Miao S; Bao J; Garcia ML; Goulet JL; Hong XJ; Kaczorowski GJ; Kayser F; Koo GC; Kotliar A; Schmalhofer WA; Shah K; Sinclair PJ; Slaughter RS; Springer MS; Staruch MJ; Tsou NN; Wong F; Parsons WH; Rupprecht KM
Bioorg Med Chem Lett; 2003 Mar; 13(6):1161-4. PubMed ID: 12643934
[TBL] [Abstract][Full Text] [Related]
40. Targeting the Kv1.3 potassium channel for immunosuppression in vascularized composite allotransplantation - a pilot study.
Hautz T; Krapf C; Grahammer J; Zelger B; Hickethier T; Seger C; Eberhart N; Wallner C; Messner F; Kotsch K; Griesmacher A; Brandacher G; Lee WP; Margreiter R; Pratschke J; Glossmann H; Schneeberger S
Transpl Int; 2013 May; 26(5):552-61. PubMed ID: 23489391
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
